In Vitro Activities and Postantifungal Effects of the Potent Dolastatin 10 Derivative Auristatin PHE

AUTOR(ES)

Woyke, Tanja

FONTE

American Society for Microbiology

RESUMO

The pentapeptide dolavaline-valine-dolaisoleuine-dolaproine-phenylalanine-methyl ester (auristatin PHE) is a derivative of the anticancer drug dolastatin 10 (dolavaline-valine-dolaisoleuine-dolaproine-dolaphenine). Broth microdilution assays with a wide variety of yeast and filamentous fungal species demonstrated the specificity of auristatin PHE for Cryptococcus neoformans and several species of Trichosporon. The duration of the postantifungal effect (PAFE) for C. neoformans was determined for exposure times ranging from 30 min to 2 h. For the derivative, a PAFE was detectable after 45 min of exposure. The effect plateaued after 1 h of exposure, with a PAFE of approximately 6.5 h at four or eight times the auristatin PHE MIC. In contrast, there was no measurable PAFE after 1 h of exposure to dolastatin 10. Human serum greatly prolonged the PAFE of auristatin PHE at eight times the MIC. Auristatin PHE arrested C. neoformans in the budding stage, possibly due to a tubulin-inhibitory action. Auristatin PHE has potential as a narrow-spectrum fungicidal agent and as a probe that can be used to study cryptococcal cell division.

Documentos Relacionados

• Specific Activities of Dolastatin 10 and Peptide Derivatives against Cryptococcus neoformans
• Differential Gene Expression in Auristatin PHE-Treated Cryptococcus neoformans
• Effect of Auristatin PHE on Microtubule Integrity and Nuclear Localization in Cryptococcus neoformans
• Potent Immunosuppressive Activities of Cytomegalovirus- Encoded Interleukin-10
• Potent Immunosuppressive Activities of Cytomegalovirus-Encoded Interleukin-10